Table 1.
Distribution of demographic and clinical characteristics of the 78 subjects included in this study.
| Category | No. | % |
|---|---|---|
| Gender | ||
| Female | 41 | 52.6 |
| Male | 37 | 47.4 |
| Age, years | ||
| <65 | 39 | 50.0 |
| 65–75 | 20 | 25.6 |
| >75 | 19 | 24.4 |
| Cardiological comorbidities | ||
| No | 55 | 70.5 |
| Yes | 17 | 21.8 |
| NA | 6 | 7.7 |
| Infections | ||
| No | 44 | 56.4 |
| Yes | 25 | 32.1 |
| NA | 9 | 11.5 |
| Anti-HCoV-229E NP IgG | ||
| Mean readings ± SD | 0.8 | 0.9 |
| Negative | 53 | 67.9 |
| Positive | 25 | 32.1 |
| Anti-HCoV-NL63 NP IgG | ||
| Mean readings ± SD | 0.9 | 1.0 |
| Negative | 53 | 67.9 |
| Positive | 25 | 32.1 |
| Anti-HCoV-229E NP IgG + anti-NL63 NP IgG | ||
| None | 49 | 62.8 |
| One | 8 | 10.3 |
| Both | 21 | 26.9 |
| Anti-HCoV-229E NP IgG + anti-HCoV-NL63 NP IgG | ||
| Negative | 49 | 62.8 |
| Positive | 29 | 37.2 |
| Anti-HCoV-OC43 NP IgG | ||
| Mean readings ± SD | 0.6 | 0.9 |
| Negative | 66 | 84.6 |
| Positive | 12 | 15.4 |
| Anti-HCoV-HKU1 NP IgG | ||
| Mean readings ± SD | 0.6 | 1.1 |
| Negative | 67 | 85.9 |
| Positive | 11 | 14.1 |
| Anti-HCoV-OC43 NP IgG + anti-HCoV-HKU1 NP IgG | ||
| None | 60 | 76.9 |
| One | 13 | 16.7 |
| Both | 5 | 6.4 |
| Anti-HCoV-OC43 IgG+ Anti-HCoV-HKU1 IgG | ||
| Negative | 60 | 76.9 |
| Positive | 18 | 23.1 |
| Anti-SARS-CoV-2 RBD IgG (Mikrogen), mean readings ± SD | 2.7 | 3.2 |
| Anti-SARS-CoV-2 S1 IgG (Mikrogen), mean readings ± SD | 3.4 | 4.0 |
| Cumulative number of anti-SARS-CoV-2 positive IgG specificities (Mikrogen) | ||
| 0 | 40 | 51.3 |
| 1 | 2 | 2.6 |
| 2 | 4 | 5.1 |
| 3 | 32 | 41.0 |
| Final anti-SARS-CoV-2 serological diagnosis (Mikrogen) | ||
| Negative | 40 | 51.3 |
| Positive | 38 | 48.7 |
| Anti-S1/S2 IgG (DiaSorin), mean readings ± SD | 109.0 | 82.2 |
| Anti-S1/S2 IgG (DiaSorin) | ||
| Negative | 6 | 7.7 |
| Positive | 24 | 30.8 |
| NA | 48 | 61.5 |
NA, not applicable; SD, standard deviation; NP nucleoprotein; RBD, receptor binding domain; S1/S2, Spike protein subunits S1 and S2.